Epigral Board Greenlights Two Projects Including 125,000 Tons Epoxy Resin Plant

Market snapshot: The Board of Directors of Epigral Limited has approved a major strategic expansion plan at its existing manufacturing site in Dahej, Gujarat. The expansion includes establishing a new Epoxy Resin & Formulations plant with a capacity of 1,25,000 Tons Per Annum (TPA) and setting up a Multi-Purpose Plant (MPP). Both projects are expected to be commissioned by H2 FY2028 with an estimated capital expenditure of ₹600 crore.

Data Snapshot

• Epigral's Board approved a new Epoxy Resin & Formulations facility with a planned capacity of 1,25,000 Tons Per Annum (TPA).
• The estimated capital expenditure for the Epoxy Resin plant and Multi-Purpose Plant is ₹600 crore, to be funded via a mix of debt and internal accruals.
• In Q1 FY27, Epigral reported a revenue of ₹709 crore, up 15% YoY, and a Profit After Tax (PAT) of ₹99 crore, up 25% YoY.

What's Changed

• Epigral is entering the Epoxy Resin segment for the first time, establishing itself as a key advanced materials player.
• The expansion shifts the company's dependency away from commoditized chlor-alkali products to high-margin specialty chemicals.
• In Q1 FY27, revenue rose 15% YoY to ₹709 crore from ₹615 crore, while net profit grew 25% YoY to ₹99 crore.

Key Takeaways

• Epigral enters the high-value advanced materials segment with a massive 1,25,000 TPA Epoxy Resin & Formulations plant.
• The strategic projects are estimated to require a capital expenditure of ₹600 crore, to be completed by H2 FY2028.
• The company expects peak revenues of ₹1,300 Crore to ₹1,500 Crore from these projects (as stated in the source alert; not independently verified).
• The Multi-Purpose Plant alone is targeting a revenue of ₹500 Crore by FY2029 or FY2030, with capex for FY2027 and FY2028 estimated at ₹400 Crore annually, funded 60% by debt and 40% by internal accruals (as stated in the source alert; not independently verified).
• Backward integration benefits are strong, with over 50% of raw materials sourced internally from the company's existing Dahej integrated complex.

SAHI Perspective

Epigral's foray into the Epoxy Resin business is a classic example of high-value forward integration. Since Epigral is already the first manufacturer of Epichlorohydrin (ECH) in India and a leading producer of Caustic Soda, it has ready access to the key raw materials required for Epoxy Resin. Sourcing over 50% of the raw material value internally not only protects Epigral from input cost volatility but also enhances the overall margins of its integrated manufacturing complex in Dahej. While the ₹600 crore capital expenditure will increase leverage temporarily, Epigral's robust cash flows (with Q1 FY27 EBITDA at ₹179 crore and net debt/EBITDA at a low 0.8x) suggest the company is well-positioned to fund this expansion without risking its balance sheet strength.

Market Implications

This expansion reduces India's heavy reliance on imports for Epoxy Resins, which are widely used in high-growth industries like wind energy (windmill blades), construction, automotive, and electronics. By establishing a large-scale domestic capacity of 1,25,000 TPA, Epigral is poised to capture a substantial share of the growing domestic demand. This is also expected to accelerate the company's structural shift away from cyclical commoditized Chlor-Alkali products towards high-margin specialty chemical derivatives.

Trading Signals

Market Bias: Bullish

Epigral's major expansion into high-margin advanced materials backed by internal raw materials, coupled with a solid Q1 FY27 performance (revenue up 15% YoY to ₹709 crore and PAT up 25% YoY to ₹99 crore), provides strong medium-term visibility.

Overweight: Specialty Chemicals, Advanced Materials, Renewable Infrastructure

Trigger Factors:

• Commissioning of the pilot plant for Epoxy Resin to facilitate customer approvals.
• Movement in global epoxy resin and caustic soda realizations.
• Quarterly progress on the ₹600 crore capex execution.

Time Horizon: Medium-term (3-12 months)

Industry Context

The domestic demand for Epoxy Resins is growing rapidly, driven by infrastructure development, automotive manufacturing, and renewable energy investments (especially wind energy). Major peers like Grasim Industries and Atul Limited are also expanding their capacities in this space. However, Epigral enjoys a unique competitive advantage due to its fully integrated complex at Dahej, which provides captive Epichlorohydrin (ECH) and Caustic Soda, ensuring superior cost efficiency compared to standalone manufacturers.

Key Risks to Watch

• Execution delays in the commissioning of the plants scheduled for H2 FY2028.
• Fluctuations in the market prices of Epoxy Resins and raw materials like ECH.
• A sharp rise in debt levels to fund the ₹600 crore expansion, though current leverage remains low at 0.8x Net Debt/EBITDA.

Recent Developments

In Q1 FY27, Epigral announced a solid financial performance, with PAT rising 25% YoY to ₹99 crore and revenue rising 15% to ₹709 crore. This follows its Q4 FY26 performance, where the company recorded its highest-ever quarterly revenue of ₹736 crore.

Closing Insight

Epigral's transition from a chlor-alkali player to a high-margin specialty chemicals leader is accelerating. The approved ₹600 crore capex for Epoxy Resin and a Multi-Purpose Plant represents a transformative leap that leverages its internal raw material base to manufacture high-value advanced materials, positioning the company for sustained long-term growth.

High Performance Trading with SAHI.